Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
NA
Total Enrollment
20000 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-01
Study Completion Date
2026-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this individual-level pragmatic randomized policy trial is to learn about the impact of behavioural nudges via mailed letters on increasing influenza and travel vaccination uptake in Alberta, Canada. The primary outcome is the proportion of adults receiving influenza and/or travel vaccination. The secondary outcome is the number of stroke events in the 6 months following vaccination. As such, this research aims to answer two key questions:
1. Do behavioural nudges increase influenza and travel vaccination in Alberta?
2. If yes, is there a decrease in the number of stroke events in the 6 months following vaccination?
The two-arm individual level pragmatic randomized trial design includes two letter dimensions, a letter (a "nudge") with an influenza and cardiovascular risk reduction message and a letter with a travel vaccination benefit message, yielding the following groups:
Letter with an influenza and cardiovascular risk reduction message Letter with a travel vaccination benefit message
1. Do behavioural nudges increase influenza and travel vaccination in Alberta?
2. If yes, is there a decrease in the number of stroke events in the 6 months following vaccination?
The two-arm individual level pragmatic randomized trial design includes two letter dimensions, a letter (a "nudge") with an influenza and cardiovascular risk reduction message and a letter with a travel vaccination benefit message, yielding the following groups:
Letter with an influenza and cardiovascular risk reduction message Letter with a travel vaccination benefit message
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment
NCT00351676
Heart Failure, Congestive
Pulmonary Disease, Chronic Obstructive
Pneumonia
+2 more
COMPLETED
PHASE4
Vascular Lifestyle-Intervention and Screening in Pharmacy
NCT02223793
Cardiovascular Diseases
Hypercholesterolemia
Dyslipidemia
+2 more
UNKNOWN
NA
Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control
NCT07228065
Hypertension
Primary Care
NOT_YET_RECRUITING
NA
Pharmacist Counseling & Self-Management Program for Asthma Patients in a Midwest Chain Pharmacy, USA
NCT07018583
Asthma Patients
NOT_YET_RECRUITING
NA
Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies
NCT07339852
Diabetes Mellitus
Hypertension
Hyperlipidaemia
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Population Setting This research project will take place in Alberta, Canada and in partnership with Mint Health and Drugs (Mint Pharmacy), an Alberta-based pharmacy corporation. Participants will be recruited through Mint Pharmacy patient records.
Inclusion Criteria 18 years of age and older by September 1, 2025, and visited a Mint Pharmacy site within 1 year of September 1, 2025.
Study Procedures Sampling Size and Strategy Mint Pharmacy will be sending a letter to all active clients (defined as an adult who filled a prescription at their pharmacy in the last year). We estimate this will be 20,000 clients with 10,000 receiving the influenza vaccine nudge and 10,000 receiving the travel vaccine nudge. This population size will allow us to detect an absolute difference of 2% between the two groups with 80% power and α= 0.05.
Recruitment and Screening Mint Pharmacy analysts will pull the study sample from their patient records, including first and last name, date of birth, and sex. The list of participants will be shared with Alberta Strategy for Patient Oriented Research (AbSPOR) analysts for randomization and data linkage. AbSPOR analysts will share the randomized list of participants, including mailing addresses, with the approved mail vendor to print and mail the appropriate nudge letter that the participant has been randomized to receive. We will stratify be geographic zone (North, Edmonton, Central, Calgary, and South) because of the geographic variation in vaccine uptake.
Intervention The Alberta Government provides free influenza vaccines from October through March annually, which corresponds with peak travel vaccine season. Travel vaccines are typically low cost or covered by private insurance. Vaccines are frequently administered by pharmacists in private pharmacies. As a pragmatic trial, there will be no in-person encounters with patients during the trial. The intervention will be delivered through mailed letters with different messages described below, to be delivered in mid-October 2025. The date of the initial letter will be defined as study baseline.
Arm 1 (Letter with an influenza risk reduction message): This letter will be signed by the pharmacist at the Mint Pharmacy site that the participant accesses and will discuss the benefits of the influenza vaccine in preventing influenza infection and cardiovascular disease risk reduction.
Arm 2 (Letter with travel vaccination benefit message): This letter will be signed by the pharmacist at the Mint Pharmacy site that the participant accesses and will discuss the benefits of travel vaccines in preventing travel related disease, such as evidence that vaccination against Hepatitis A, a common travel vaccination, is 90-95% effective in preventing Hepatitis A infection.
Outcomes Primary outcome: receipt of an influenza and/or travel vaccine on or before March 1, 2026.
Secondary outcome: Number of hospitalizations and emergency department visits for influenza and the number of stroke events on or before September 30, 2026 (6 months following influenza vaccination programs)
Blinding Study researchers will be blind to the participants' group allocation. Participants will not be aware that the communications they receive are part of a research study. Because of this deception, we are requesting a waiver of consent and not attaching a patient information form or informed consent form.
Waiver of Consent
A waiver of consent is necessary both logistically and to limit bias. It is not feasible to obtain informed consent with a sample size n=5190. Additionally, because this study aims to investigate health behaviour, obtaining prior consent alerts participants to the existence of other health messages and may affect their response to the health message they do receive, introducing response bias. Our firm commitment to patient engagement and robust patient engagement plan also reduces participant risk. As per the Tri-Council Policy Statement (TCPS) 2.0, Article 3.7A, alterations to the consent process (including waiver of consent) are appropriate when:
1. The research involves no more than minimal risk to the participant
2. The alteration to consent requirements is unlikely to adversely affect the welfare of participants
3. It is impossible or impractical to carry out the research and to address the research questions properly, given the research design, if the prior consent of participants is required
The proposed study meets the above TCPS 2.0 requirements for alterations to the consent process.
Data Collection Mint Pharmacy analysts will pull the study sample from their patient records, including first and last name, date of birth, and sex. The list of participants will be shared with Alberta Strategy for Patient Oriented Research (AbSPOR) analysts for randomization and data linkage. AbSPOR analysts will share the randomized list of participants, including mailing addresses, with the approved mail vendor to print and mail the appropriate nudge letter that the participant has been randomized to receive. AbSPOR analysts will gather vaccination data from the Alberta Health Immunization and Adverse Reactions Following Immunization (IMM/ARI) database by linking participant health numbers to determine how many participants received a vaccination. The IMM/ARI database is the most comprehensive vaccination database as it is where all vaccinations are required to be reported in Alberta with nearly 100% coverage. AbSPOR analysts will gather hospitalization, emergency department visit, and the number of stroke events from the Alberta Health Discharge Abstract Database (DAD) using participant health numbers. Influenza and stroke events will be identified using ICD-10 codes. This data collection will be continuous from April 1st, 2026, through September 30th, 2026, six-months following the influenza vaccination program. Data linkage and cross-reference will be conducted by AbSPOR, who will share de-identified data with the research team in either de-identified or aggregate form for analysis.
Data Analysis Data analysis will be conducted by members of the research team using the de-identified data provided by AbSPOR. Statistical comparisons will be performed according to the intention-to-treat principle. We will report the proportion of adults who received influenza vaccination and travel vaccination (any vaccines, specific vaccine types, and full series of vaccines) in each group along with 95% confidence intervals. We will model the risk difference for each type of nudge compared to the comparison group) in separate models, including adjustment for multiple comparisons. As a secondary analysis, we will assess time to vaccination in the influenza letter group compared to the travel vaccine letter group. To assess impact of vaccine uptake on influenza and stroke events, we will compare the number of events in one intervention group with the number of stroke events in the comparison group. The primary analysis will be conducted on the as-randomized populations (intention-to-treat analysis).
Inclusion Criteria 18 years of age and older by September 1, 2025, and visited a Mint Pharmacy site within 1 year of September 1, 2025.
Study Procedures Sampling Size and Strategy Mint Pharmacy will be sending a letter to all active clients (defined as an adult who filled a prescription at their pharmacy in the last year). We estimate this will be 20,000 clients with 10,000 receiving the influenza vaccine nudge and 10,000 receiving the travel vaccine nudge. This population size will allow us to detect an absolute difference of 2% between the two groups with 80% power and α= 0.05.
Recruitment and Screening Mint Pharmacy analysts will pull the study sample from their patient records, including first and last name, date of birth, and sex. The list of participants will be shared with Alberta Strategy for Patient Oriented Research (AbSPOR) analysts for randomization and data linkage. AbSPOR analysts will share the randomized list of participants, including mailing addresses, with the approved mail vendor to print and mail the appropriate nudge letter that the participant has been randomized to receive. We will stratify be geographic zone (North, Edmonton, Central, Calgary, and South) because of the geographic variation in vaccine uptake.
Intervention The Alberta Government provides free influenza vaccines from October through March annually, which corresponds with peak travel vaccine season. Travel vaccines are typically low cost or covered by private insurance. Vaccines are frequently administered by pharmacists in private pharmacies. As a pragmatic trial, there will be no in-person encounters with patients during the trial. The intervention will be delivered through mailed letters with different messages described below, to be delivered in mid-October 2025. The date of the initial letter will be defined as study baseline.
Arm 1 (Letter with an influenza risk reduction message): This letter will be signed by the pharmacist at the Mint Pharmacy site that the participant accesses and will discuss the benefits of the influenza vaccine in preventing influenza infection and cardiovascular disease risk reduction.
Arm 2 (Letter with travel vaccination benefit message): This letter will be signed by the pharmacist at the Mint Pharmacy site that the participant accesses and will discuss the benefits of travel vaccines in preventing travel related disease, such as evidence that vaccination against Hepatitis A, a common travel vaccination, is 90-95% effective in preventing Hepatitis A infection.
Outcomes Primary outcome: receipt of an influenza and/or travel vaccine on or before March 1, 2026.
Secondary outcome: Number of hospitalizations and emergency department visits for influenza and the number of stroke events on or before September 30, 2026 (6 months following influenza vaccination programs)
Blinding Study researchers will be blind to the participants' group allocation. Participants will not be aware that the communications they receive are part of a research study. Because of this deception, we are requesting a waiver of consent and not attaching a patient information form or informed consent form.
Waiver of Consent
A waiver of consent is necessary both logistically and to limit bias. It is not feasible to obtain informed consent with a sample size n=5190. Additionally, because this study aims to investigate health behaviour, obtaining prior consent alerts participants to the existence of other health messages and may affect their response to the health message they do receive, introducing response bias. Our firm commitment to patient engagement and robust patient engagement plan also reduces participant risk. As per the Tri-Council Policy Statement (TCPS) 2.0, Article 3.7A, alterations to the consent process (including waiver of consent) are appropriate when:
1. The research involves no more than minimal risk to the participant
2. The alteration to consent requirements is unlikely to adversely affect the welfare of participants
3. It is impossible or impractical to carry out the research and to address the research questions properly, given the research design, if the prior consent of participants is required
The proposed study meets the above TCPS 2.0 requirements for alterations to the consent process.
Data Collection Mint Pharmacy analysts will pull the study sample from their patient records, including first and last name, date of birth, and sex. The list of participants will be shared with Alberta Strategy for Patient Oriented Research (AbSPOR) analysts for randomization and data linkage. AbSPOR analysts will share the randomized list of participants, including mailing addresses, with the approved mail vendor to print and mail the appropriate nudge letter that the participant has been randomized to receive. AbSPOR analysts will gather vaccination data from the Alberta Health Immunization and Adverse Reactions Following Immunization (IMM/ARI) database by linking participant health numbers to determine how many participants received a vaccination. The IMM/ARI database is the most comprehensive vaccination database as it is where all vaccinations are required to be reported in Alberta with nearly 100% coverage. AbSPOR analysts will gather hospitalization, emergency department visit, and the number of stroke events from the Alberta Health Discharge Abstract Database (DAD) using participant health numbers. Influenza and stroke events will be identified using ICD-10 codes. This data collection will be continuous from April 1st, 2026, through September 30th, 2026, six-months following the influenza vaccination program. Data linkage and cross-reference will be conducted by AbSPOR, who will share de-identified data with the research team in either de-identified or aggregate form for analysis.
Data Analysis Data analysis will be conducted by members of the research team using the de-identified data provided by AbSPOR. Statistical comparisons will be performed according to the intention-to-treat principle. We will report the proportion of adults who received influenza vaccination and travel vaccination (any vaccines, specific vaccine types, and full series of vaccines) in each group along with 95% confidence intervals. We will model the risk difference for each type of nudge compared to the comparison group) in separate models, including adjustment for multiple comparisons. As a secondary analysis, we will assess time to vaccination in the influenza letter group compared to the travel vaccine letter group. To assess impact of vaccine uptake on influenza and stroke events, we will compare the number of events in one intervention group with the number of stroke events in the comparison group. The primary analysis will be conducted on the as-randomized populations (intention-to-treat analysis).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Stroke
Influenza Human
Influenza Vaccines
Health Behavior Change
Travel-Related Illness
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
A two-arm individual-level pragmatic randomized policy trial with two letter dimensions, 1) a letter with an influenza and cardiovascular risk reduction message, and 2) a letter with a travel vaccination benefit message, yielding the following groups:
Letter with an influenza and cardiovascular risk reduction message Letter with a travel vaccination benefit message
Letter with an influenza and cardiovascular risk reduction message Letter with a travel vaccination benefit message
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Influenza and Cardiovascular Risk Reduction
Participants randomized to the Influenza Risk Reduction arm will receive a letter encouraging ("nudging") influenza vaccination as an influenza and cardiovascular risk reduction method.
Group Type
EXPERIMENTAL
Behavioural Nudge (Influenza Risk Reduction)
Intervention Type
BEHAVIORAL
A behavioural nudge via mailed letter that discusses the benefits of the influenza vaccine in preventing influenza infection and reducing cardiovascular risk.
Travel Vaccination Benefit
Participants randomized to the Travel Vaccination Benefit arm will receive a letter encouraging ("nudging") travel vaccination as a health benefit by reducing the risk of contracting a travel-related illness.
Group Type
EXPERIMENTAL
Behavioural Nudge (Travel Vaccination Benefit)
Intervention Type
BEHAVIORAL
A behavioural nudge via mailed letter that discusses the benefits of travel vaccines in preventing travel-related illnesses.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Behavioural Nudge (Influenza Risk Reduction)
A behavioural nudge via mailed letter that discusses the benefits of the influenza vaccine in preventing influenza infection and reducing cardiovascular risk.
Intervention Type
BEHAVIORAL
Behavioural Nudge (Travel Vaccination Benefit)
A behavioural nudge via mailed letter that discusses the benefits of travel vaccines in preventing travel-related illnesses.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visited a Mint Pharmacy site within 1 year of enrollment date
* 18 years of age and older by enrolment date
* 18 years of age and older by enrolment date
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alberta Health services
OTHER
Sponsor Role
collaborator
Mint Health + Drugs
UNKNOWN
Sponsor Role
collaborator
University of Calgary
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amity Quinn
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Public Health Agency of Canada, Statement on Seasonal Influenza Vaccine for 2014-2015. 2014, National Advisory Committee on Immunization: Ottawa.
Reference Type
BACKGROUND
McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003 May 21;289(19):2545-53. doi: 10.1001/jama.289.19.2545.
Reference Type
BACKGROUND
Renosa MDC, Landicho J, Wachinger J, Dalglish SL, Barnighausen K, Barnighausen T, McMahon SA. Nudging toward vaccination: a systematic review. BMJ Glob Health. 2021 Sep;6(9):e006237. doi: 10.1136/bmjgh-2021-006237.
Reference Type
BACKGROUND
Patel MS, Milkman KL, Gandhi L, Graci HN, Gromet D, Ho H, Kay JS, Lee TW, Rothschild J, Akinola M, Beshears J, Bogard JE, Buttenheim A, Chabris C, Chapman GB, Choi JJ, Dai H, Fox CR, Goren A, Hilchey MD, Hmurovic J, John LK, Karlan D, Kim M, Laibson D, Lamberton C, Madrian BC, Meyer MN, Modanu M, Nam J, Rogers T, Rondina R, Saccardo S, Shermohammed M, Soman D, Sparks J, Warren C, Weber M, Berman R, Evans CN, Lee SH, Snider CK, Tsukayama E, Van den Bulte C, Volpp KG, Duckworth AL. A Randomized Trial of Behavioral Nudges Delivered Through Text Messages to Increase Influenza Vaccination Among Patients With an Upcoming Primary Care Visit. Am J Health Promot. 2023 Mar;37(3):324-332. doi: 10.1177/08901171221131021. Epub 2022 Oct 4.
Reference Type
BACKGROUND
Modin D, Johansen ND, Vaduganathan M, Bhatt AS, Lee SG, Claggett BL, Dueger EL, Samson SI, Loiacono MM, Kober L, Solomon SD, Sivapalan P, Jensen JUS, Jean-Marie Martel C, Valentiner-Branth P, Krause TG, Biering-Sorensen T. Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial. Circulation. 2023 May 2;147(18):1345-1354. doi: 10.1161/CIRCULATIONAHA.123.064270. Epub 2023 Mar 5.
Reference Type
BACKGROUND
Johansen ND, Vaduganathan M, Bhatt AS, Lee SG, Modin D, Claggett BL, Dueger EL, Samson SI, Loiacono MM, Kober L, Solomon SD, Sivapalan P, Jensen JUS, Martel CJ, Valentiner-Branth P, Krause TG, Biering-Sorensen T. Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial. Lancet. 2023 Apr 1;401(10382):1103-1114. doi: 10.1016/S0140-6736(23)00349-5. Epub 2023 Mar 5.
Reference Type
BACKGROUND
Saaksvuori L, Betsch C, Nohynek H, Salo H, Sivela J, Bohm R. Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland. PLoS Med. 2022 Feb 9;19(2):e1003919. doi: 10.1371/journal.pmed.1003919. eCollection 2022 Feb.
Reference Type
BACKGROUND
Holodinsky JK, Zerna C, Malo S, Svenson LW, Hill MD. Association between influenza vaccination and risk of stroke in Alberta, Canada: a population-based study. Lancet Public Health. 2022 Nov;7(11):e914-e922. doi: 10.1016/S2468-2667(22)00222-5.
Reference Type
BACKGROUND
Yu AYX, Krahn M, Austin PC, Rashid M, Fang J, Porter J, Vyas MV, Bronskill SE, Smith EE, Swartz RH, Kapral MK. Sex differences in direct healthcare costs following stroke: a population-based cohort study. BMC Health Serv Res. 2021 Jun 29;21(1):619. doi: 10.1186/s12913-021-06669-w.
Reference Type
BACKGROUND
Holodinsky JK, Lindsay P, Yu AYX, Ganesh A, Joundi RA, Hill MD. Estimating the Number of Hospital or Emergency Department Presentations for Stroke in Canada. Can J Neurol Sci. 2023 Nov;50(6):820-825. doi: 10.1017/cjn.2022.338. Epub 2022 Dec 20.
Reference Type
BACKGROUND
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 Jun 28;25(27):5086-96. doi: 10.1016/j.vaccine.2007.03.046. Epub 2007 Apr 20.
Reference Type
BACKGROUND
Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in Canada, 1992-2009. PLoS One. 2013 Nov 27;8(11):e80481. doi: 10.1371/journal.pone.0080481. eCollection 2013.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.alberta.ca/stats/dashboard/respiratory-virus-dashboard.htm
Alberta Government. Alberta Influenza Statistics. 2023. \[cited 2023 May 25\];
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB25-1205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effectiveness of and Satisfaction With a Pharmacist-managed Travel Medicine Clinic
NCT02625129
COMPLETED
Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial
NCT04776161
COMPLETED
NA
Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators
NCT06142838
RECRUITING
NA
Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People
NCT03671629
RECRUITING
NA
Over-the-Counter Medication Usage
NCT00439348
COMPLETED
NA
CARD for Community Pharmacy Vaccinations
NCT06098703
UNKNOWN
NA
Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice
NCT01351441
COMPLETED
NA
A Pharmacist-led Transitions of Care Program
NCT04556786
COMPLETED
NA
Effect of a trAnSitional Pharmacist Intervention in geRiatric Inpatients on Hospitals Visits After dischargE
NCT04617340
COMPLETED
NA
Community Pharmacy Assisting in Total Cardiovascular Health
NCT01509014
UNKNOWN
NA
MinMed: Do Older Adults do Better With Less Medication
NCT05307666
ENROLLING_BY_INVITATION
PHASE4
E-mails to Nudge Safer and Better-Informed Prescribing of Risky Drugs
NCT06443385
ACTIVE_NOT_RECRUITING
NA
Improving Adherence to Pharmacological Treatment
NCT00848224
COMPLETED
NA
Carefully seLected and Easily Accessible at No Charge Medications
NCT02744963
UNKNOWN
NA
Pharmacist-led Interventions to Improve Medication Use
NCT05346770
UNKNOWN
The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians
NCT00761904
UNKNOWN
NA
Effectiveness of a Medication Wallet Card
NCT02820129
COMPLETED
PHASE1
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
NCT04645836
COMPLETED
NA
Enhancing Timely Access to Medication Changes: The Role of Pharmacists in Overcoming Transitions of Care Challenges
NCT07018232
COMPLETED
Improvement of Intentional and Unintentional Non-adherence in the Elderly
NCT01512238
COMPLETED
Conversation With Family Doctor to Increase COVID-19 Vaccine Uptake
NCT05207137
COMPLETED
NA
Over-the-counter (OTC) Labels for Older Adults
NCT04345731
COMPLETED
NA
Benefit of a Collaborative Approach to Improve the Quality of Medicines Use in Elderly Inpatients
NCT00279656
COMPLETED
PHASE4
Personalized Health Assessment Related to Medications (Project PHARM)
NCT03037476
COMPLETED
NA
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention
NCT02215408
COMPLETED
NA